Creo Medical inks collaboration agreement with Intuitive

Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems.

The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday in New York, ISGR shares are up slightly to $221 apiece on the Nasdaq.

Based in the U.K., Creo is developing and commercializing a suite of electrosurgical medical devices. Its patented Kamaptive technology combines adaptive bipolar radiofrequency (RF) and super high-frequency microwave energy in the CROMA advanced energy platform. Kamaptive can dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue, according to Creo.

Get the full story on our sister site Medical Design & Outsourcing. 

Read more
  • 0

Creo Medical inks collaboration agreement with Intuitive

Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems.

The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday in New York, ISGR shares are up slightly to $221 apiece on the Nasdaq.

Based in the U.K., Creo is developing and commercializing a suite of electrosurgical medical devices. Its patented Kamaptive technology combines adaptive bipolar radiofrequency (RF) and super high-frequency microwave energy in the CROMA advanced energy platform. Kamaptive can dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue, according to Creo.

The agreement with Intuitives outlines how the companies will conduct joint clinical studies and includes a number of milestone …

Read more
  • 0

Junkosha honors Creo Medical CTO as the winner of its its Technology Innovator of the Year Awards

Junkosha announced today that it is awarding Creo Medical founder and CTO Chris Hancock with a $25,000 prize as the winner of its inaugural Technology Innovator of the Year Awards.

The U.K.-based company has created an advanced energy multimodality instrument developed for flexible endoscopy. According to Junkosha, Creo Medical’s technology combines the benefits of bipolar RF and super high-frequency microwave energy to provide the ability to dissect, resect, coagulate and inject in a single device — producing results that could reduce cancer recurrence.

“Chris’ breakthrough technology holds the potential to transform the point of treatments for a range of cancers. Overall, Chris’ achievement is one we can use as a yardstick to measure others in future years,” said Joe Rowan, Junkosha’s president and CEO in the U.S. and Europe.

Said Junkosha CEO Mamoru Sogo: “We believe that enabling innovators, like Creo Medical, is central to th…

Read more
  • 0